Judith Dalmau Moreno
Dr. Judith Dalmau graduated in Biotechnology from the Autonomous University of Barcelona (UAB) in 2004 and obtained an MSc in Drug Design and Biomedical Sciences from Edinburgh Napier University in 2005.
In 2006 she launched a career in HIV research on joining Dr. Javier Martinez-Picado’s team at IrsiCaixa, obtaining her PhD in 2014. She has participated in several projects as a researcher and as a designer and coordinator of clinical cohorts and has also coordinated national and international projects. Her main line of research (the topic of her thesis) is the study of extreme phenotypes of HIV disease progression, including rapid progressors, viraemic non-progressors and exposed non-infected individuals. In June 2014 she joined the Research and Innovation Management Office (RIMO) at IrsiCaixa as project manager for the GREC and VIRIEVAC research groups. Her current professional position reflects research, cohort coordination and management roles.
Dr. Dalmau has published some 20 papers in high-impact journals, has participated in numerous international conferences and workshops and has been involved in several Spanish- and European-funded collaborative projects. She has been a lecturer on the MSc in AIDS Pathogenesis and Treatment since 2011 and also actively participates in many community outreach activities.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART.
In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection.
HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.
Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.